Emerging evidence indicates an important role for breast cancer resistance protein (BCRP) in limiting brain penetration of substrate drugs. While in vitro Transwell ® assays can provide an indication of BCRP substrate potential, the predictability of these to in vivo brain penetration is still under debate. The present study examined the correlation of BCRP membrane protein expression level and transcellular transport activity across MDCKII monolayers. We expressed human BCRP or murine BCRP1 in MDCKII wild-type cells using BacMam2 virus transduction. The selective Pglycoprotein (P-gp) inhibitor LY335979 (1 M) was included in transport medium to measure BCRP-mediated transcellular transport for P-gp and BCRP co-substrates.
Introduction
Drugs designed for brain disorders should be able to the cross blood-brain barrier (BBB) at appropriate concentrations, to exert their desired pharmacology. The strength of the BBB is the result of the very tight junctions between the endothelial cells, polarized active efflux transporters and limited pinocytosis. The major efflux transporters expressed at the luminal side of the BBB are ATP-binding cassette (ABC) family of transporters including P-glycoprotein (P-gp; ABCB1) and breast cancer resistance protein (BCRP; ABCG2). The prominent role of P-gp in limiting entry of various drugs into the central nervous system (CNS) has been well appreciated (Doran et al., 2005; Schinkel et al., 1996; Shen and Zhang, 2010) . Thus polarized cell monolayers such as MDCK or Caco2 with expression of human P-gp were deployed early by the pharmaceutical industry to triage drug candidates in CNS drug discovery.
The predictive value of these in vitro assays was widely recognized and strong P-gp substrates were unarguably de-prioritized for centrally acting compounds (Feng et al., 2008; Kikuchi et al., 2013; Mahar Doan et al., 2002; Yamazaki et al., 2001 ).
BCRP (ABCG2) is the second member of the G subfamily of ABC transporter proteins. BCRP is constitutively expressed in human tissues such as CNS (luminal membrane of BBB endothelia), intestine, kidney, liver, placenta, testis, and stem cells, contributing to the absorption, distribution, and elimination of drugs and endogenous compounds (Schnepf and Zolk, 2013) . Since its discovery in 1998, many drugs and endogenous substances have been identified to be transported by BCRP (Doyle et al., 1998; Lee et al., 2015) . Brain penetration studies in naï ve, , , Bcrp1(-/-) mice or rats clearly illustrated the restrictive effect of BCRP1 on brain disposition for substrate drugs, such as cancer therapeutics, dantrolene and phytoestrogens (Enokizono et al., 2007; Schnepf and Zolk, 2013) .
Recent liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based
proteomic analyses revealed that BCRP is the most abundant transporter in human BBB and shows approximately 2-fold higher expression in human than in rodent. This is in contrast to about 2-3-fold lower P-gp expression at BBB in human than rodent (Hoshi et al., 2013; Kamiie et al., 2008; Uchida et al., 2011b) . In addition, BCRP expression is up-regulated in some neurodegenerative diseases such as Alzheimer disease and amyotrophic lateral sclerosis patients (Jablonski et al., 2012; Xiong et al., 2009 ). These data could imply a more prominent role of BCRP in brain penetration in diseased human as compared with mice and rats.
Despite this emerging evidence, BCRP is largely overlooked in CNS drug discovery programs due to several reasons. First, BCRP and P-gp share largely overlapping substrate specificity. These transporters cooperate to limit the brain distribution of their co-substrates and compensate for each other when the function of one of these is impaired. Teasing out BCRP specific impact on drug brain penetration in intact systems is not an easy task, in part due to the limited specificity of substrates and inhibitors. In addition, utilization of mouse or rat as the most-evaluated preclinical species to examine the role of efflux transporters at BBB in brain penetration may underestimate and reinforce the contribution of BCRP and P-gp, respectively, due to species difference in protein expression. Second, BCRP is distinct from P-gp and MRPs, as it is a half-transporter that functions as a dimer or oligomer (Poguntke et al., 2010) . The structural understanding of drug binding and transport by BCRP is still incomplete. Structural and physicochemical properties governing the interaction with BCRP remain largely unexplored. This complexity poses a lot of uncertainties for the project teams to know how to walk away from this liability. Third, predictive value of in vitro BCRP transport assays remains controversial. BCRP was reported to play a DMD # 74245 6 minimal role at the BBB in vivo in spite of mediating transport of various compounds in vitro (Zhao et al., 2009) . Another study did not demonstrated a positive relationship between in vivo and in vitro BCRP activities in brain and testis penetration for eight compounds (Enokizono et al., 2008) . These knowledge gaps cast doubt on the benefit of compound screening against BCRP in CNS discovery projects.
In the present study, we aimed to examine the relationship between BCRP protein expression and transcellular transport activity using newly constructed human and murine BCRP expressing MDCKII cells. We have also examined species difference in mouse and human BCRP transport activities for 12 drugs. Finally, we examined the relationship between BCRP efflux ratio and rodent brain-to-blood unbound concentration ratio for 25 compounds, which were BCRP but not, or weak P-gp substrates. 
Materials and Methods

Materials
where V D and V R are donor and receiver well volumes in mL, respectively; A is the membrane surface area in cm 2 ; t is transport time in seconds; C R (t) and C D (t) are the measured mass spectrometric response or concentration of test compound in the receiver and donor well at time t (90 min), respectively; C D (t0) is the measured mass spectrometric response or concentration of test compound in the initial donor solution at time 0. This equation was also used to determine the membrane permeability of lucifer yellow.
Efflux ratio (ER) is defined as permeability ratio of basolateral-to-apical to apical-tobasolateral direction. Corrected efflux ratio is ratio of ER in the absence of inhibitor to presence of inhibitor completely abolishing transporter activity. This is introduced to account for any involvement of endogenous transporters in MDCKII-WT cells in transcellular transport of test compounds. Table 1 .
Quantification of Test Compounds in Transport Samples by LC-MS/MS.
Quantification of drugs in MDCKII transport
Protein quantification of human BCRP and murine BCRP1 by LC-MS/MS
Protein quantification of human BCRP in BacMam2-BCRP transduced or murine BCRP1 in BacMam2-Bcrp1 transduced MDCKII membrane extracts was conducted by mass spectrometry-based targeted proteomics using validated LC-MS/MS methods. Briefly, the cells were harvested from semi-permeable membranes in the Transwell ® inserts using the extraction buffer I of ProteoExtract TM membrane extraction kit. The total membrane proteins were isolated and digested using the procedure outlined before (Kamiie et al., 2008; Uchida et al., 2013) .
Chromatographic and spectrometric conditions for protein quantification of BCRP and BCRP1 is described below. Trypsin digest (8 l Accuracy and precision of the assay was >80% and <20% respectively. BCRP and BCRP1 protein expression data (picomoles per milligram) were expressed relative to the total protein content of the isolated membrane, as determined by the Pierce ® BCA Protein Assay Kit. All samples were digested and measured in duplicate.
Relationship between efflux ratio (ER) and the efflux activity
Relationship between efflux ratio (ER) and the efflux activity (PS efflux ) for BCRP across MDCKII monolayers was adapted from a three-compartment model (apical, cellular, and basolateral) described previously (Kalvass and Pollack, 2007) :
where PS efflux is BCRP-mediated efflux activity; PS is the passive permeabilitysurface area product; ER is permeability ratio of basolateral-to-apical to apical-tobasolateral direction. Corrected efflux ratio was also used herein to account for any influence introduced by endogenous transporters in MDCKII-WT cells. Based on eq.
(3), PS efflux is quantitatively proportional to ER-1 multiplied by the passive permeability.
Dantrolene is a specific BCRP substrate and was used as a reference compound in 
Substitution of eq.3 into eq. 4 and rearrangement yield eq.5:
In vivo efflux ratio (ER in vivo ) was defined as the brain-to-plasma (blood) ratio in Bcrp-deficient animals divided by the brain-to-blood (plasma) ratio in Bcrpcompetent animals at steady state. Unbound brain-to-blood (plasma) concentration ratio (K p,uu ) of a discovery compound can be described by reciprocal of in vivo efflux ratio (Uchida et al., 2011a In all cases, p < 0.05 was considered to be statistically significant.
Results
Construction of MDCKII Monolayers Expressing BCRP or BCRP1
BacMam2 viruses carrying BCRP or Bcrp1 cDNA in DMEM medium was dosed into the apical side of Transwell ® inserts at a designated multiplicity of infection (MOI).
Transport studies were carried out two days after transduction of BacMam2. TEER values of MDCKII monolayers were elevated after BacMam2 virus transduction. The extent of increase in TEER values correlated positively with MOI of BacMam2 (Fig.   1A ). Low permeability of paracellular marker lucifer yellow (typically < 20 nm/s) confirmed tightness of MDCKII-Bcrp1 or MDCKII-BCRP monolayers. MDCKII-WT cells expressed endogenous canine P-gp, transport activity of which was probed by amprenavir, a P-gp specific substrate. ER of amprenavir was reduced along with increasing transport of dantrolene, a specific probe substrate of BCRP1 (Fig. 1B) .
This was consistent with reverse correlation of canine P-gp and BCRP mRNA levels in BacMam2-BCRP transduced MDCKII cells (data not shown). Inclusion of 1 µM of P-gp specific inhibitor LY335979 in transport medium completely inhibited endogenous P-gp activity (Shepard et al., 2003) , with no effect on BCRP1 activity in MDCKII cells (Fig. 1C) . Inter-batch variability in BCRP transport activity was notable (Fig. 1D) . ER of dantrolene was 15.9 ± 8.9 in 16 consecutive experiments with coefficient of variation of 56% in MDCKII-BCRP cells. ER of dantrolene collapsed to around unity (0.935 ± 0.307) in the presence of 0.2 µM of BCRP specific inhibitor Ko143 in transport medium (Allen et al., 2002) . (Balogh et al., 2013; Peng et al., 2015) . Dantrolene, coumestrol, daidzein, and genistein are BCRP specific substrates (Enokizono et al., 2007; Fuchs et al., 2014) . Transport of these four compounds across MDCKII monolayers with different level of BCRP expression was examined (Table 1 and Supplemental Table 3 ). The P-gp specific inhibitor LY335979 was included in transport medium with prazosin, a known P-gp and BCRP co-substrate 
Correlation between BCRP Membrane Protein Concentration and Transcellular
MDCKII
Correlation between BCRP and BCRP1 Efflux Ratios across MDCKII Monolayers
The in vitro BCRP1 and BCRP efflux ratios were assessed using a set of drugs including P-gp and BCRP co-substrates across MDCKII monolayers. Endogenous canine P-gp activity was inhibited by including LY335979 (1 µM) in transport medium. To avoid data difference due to any inter-batch variation in BCRP expression, the 12 drugs were evaluated in a single experiment. One micromolar donor concentration was used for all drugs. All the selected drugs were identified to be murine and human BCRP substrates. ERs for those drugs were greater than 2 and collapsed to around or below unity in the presence of the BCRP specific inhibitor Ko143 (Table 3 and Table 4 ). When the impact of BCRP on directional transport was ranked across all tested drugs, considerable overlap between human and mouse was observed. Corrected efflux ratios of BCRP1 and BCRP were within two-fold for all drugs except flavopiridol, which had 2.2-fold higher efflux in human (Fig. 4) .
Discussion
Screening for BCRP substrates in CNS drug discovery is mainly issue-driven and this typically takes place when a discovery compound with high passive permeability has a low unbound brain-to-blood (plasma) ratio (K p,uu ) and is not a strong P-gp substrate (Di et al., 2013; Poirier et al., 2014) . A challenge facing project teams is how to contextualize the in vitro MDCKII-BCRP transport data. To predict transportermediated disposition at BBB, physiologically-based pharmacokinetic (PBPK) approaches use in vitro data from over-expressing cell lines and scale these to the in vivo, by correcting the differences in transporter protein expression via in vitro-in vivo extrapolation. This approach requires making two assumptions. First, passive permeability is similar across epithelial (MDCK) and endothelial (BBB) membrane.
Second, there is a linear correlation between expression and activity of the transporter protein (Kumar et al., 2015) . Available evidence supports the hypothesis that there is no substantial difference in passive permeability across epithelial and endothelial membranes (Liu et al., 2014; Uchida et al., 2011a) . The current study aims to examine the validity of the second assumption for BCRP, using MDCKII-BCRP and MDCKIIBcrp1 monolayers. Our data demonstrate a linear correlation between BCRP membrane protein expression and BCRP-mediated transcellular transport activity across MDCKII monolayers, within the efflux ratios investigated. This implies that it is feasible to predict BCRP-mediated in vivo impact on brain penetration using a BCRP expressing MDCKII Transwell ® system. This was earlier exemplified by P-gp substrates that showed transcellular transport activity was proportional to the transporter expression levels (Tachibana et al., 2010) . Successful reconstruction of in vivo brain distribution of P-glycoprotein substrates has been based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and in vitro transporter expression in mice and monkey (Uchida et al., 2011a; Uchida et al., 2014) .
Dantrolene is a specific BCRP substrate with well characterized BBB transport profiles in preclinical species. We use this reference drug as an indicator of BCRP competency in Transwell ® system. A review of literature showed that the in vivo brain penetration efflux ratios of dantrolene in Bcrp1(-/-) to wild type mice and rats were 6.30 and 3.30 at steady state, respectively, and mean Bcrp expression at mouse, rat, and human BBB was 3.37, 4.15, and 7.15 fmol/µg protein, respectively (Table 5) . By averaging the Bcrp expression and in vivo brain penetration efflux ratios in mice and rats and assuming no species difference in BCRP transport activity, we predicted the human in vivo efflux ratio (ER in vivo, Dan ) to be 9.1 and unbound brain-to-plasma concentration ratio 0.11 (Table 4) (Kumata et al., 2012) .
To verify this contextualization approach, we applied this method to twenty-two proprietary discovery compounds and three phytoestrogens including coumestrol, daidzein, and genistein, which are BCRP but not or weak P-gp substrates (Supplemental Table 4 ). We observed good correlation of restricted brain penetration with benchmarked in vitro efflux ratios in rodents (Fig. 5) . Compromised brain penetration (K p,uu < 0.3) is correctly predicted when (ER in vitro, test compound -1)/(ER in vitro, Dan -1) is greater than 0.6 (Quadrant I, 0.6 is derived from mean in vivo efflux ratio of dantrolene in rat and mouse). Some compounds show greater restriction in brain penetration than expected (Quadrant IV), likely due to additional BBB efflux mechanisms or species difference in BCRP or P-gp transport. In our experience, it is not unusual for a compound to have limited brain penetration (e.g. K p,uu < 0.3), even though it is not a P-gp and BCRP substrate and has high passive permeability. It is possible that member(s) of the MRP family of transporters are involved, or some other yet-to-be-identified efflux pathways. This highlights the gap in our understanding of the very intricate BBB. Empirically, efflux ratio of BCRP greater than 5 was used as a "red flag" of brain penetration impairment. However, this empirical approach does not consider inter-batch BCRP expression variability and may only be applied in our lab.
The proposed contextualization approach has been improved by addressing this issue and may be transferable to other labs.
On a simpler scale, we are able to manipulate the in vitro system to minimize impact of other transporters, as the endogenous canine transporters expressed on MDCKII cells may confound the transport data of P-gp and BCRP co-substrates. MDCKII-WT cells express canine P-gp but not BCRP. In addition, endogenous P-gp expression can be impacted by BacMam virus load (Liu et al., 2015) . In prior studies, BCRPexpressing in vitro Transwell ® system was not found to be predictive of in vivo transport activity (Enokizono et al., 2008; Zhao et al., 2009 ), likely because Pgp/BCRP co-substrates were included and the activity of endogenous P-gp was ignored. In this study, inclusion of P-gp specific inhibitor LY335979 in transport medium inhibited the endogenous P-gp activity. Quantitative proteomics combined with transport studies in this relatively "pure" BCRP functioning in vitro system may be a very useful method to predict the fraction of drug transported by BCRP in vivo across BBB. This parameter is critical when predicting the K p,uu of a drug and the significance of transporters in determining brain penetration of a drug . In theory, the additive effect of P-gp and Bcrp on brain-to-plasma ratio for co-substrates can be reconstructed by their respective contribution to the net efflux at the BBB (Kodaira et al., 2010).
The mouse BCRP1 and human BCRP amino-acid sequences are 81% identical and 86% homologous, with very high homology in the ATP binding region (Doyle and Ross, 2003) . Despite broad use of Bcrp1 knockout mice in exploring the effect of this transporter on drug disposition, little is known about differences in the kinetics of BCRP-mediated drug transport between human and mouse. Use of newly introduced BCRP expressing MDCKII monolayers without endogenous canine P-gp activity allows us to examine species difference in murine and human BCRP-mediated transcellular transport. In order to control inter-batch variability in BCRP expression, 12 drugs were evaluated simultaneously in a single experiment. Good concordance of murine and human BCRP efflux ratios across MDCKII monolayers was observed. A further comparative study with a range of chemotypes using these systems is required.
Meaningful comparison can only be obtained by close monitoring of BCRP expression among different batches of MDCKII cells.
In summary, we have constructed human BCRP and murine BCRP1 expressing MDCKII cells by BacMam2 virus transduction. Inclusion of P-gp specific inhibitor LY335979 in the test system allowed us to create a relatively "clean" system to investigate BCRP-mediated transcellular transport across MDCKII monolayers.
Linear correlation of membrane protein expression levels with transcellular transport activity for BCRP was observed within the efflux ratios investigated. We proposed an approach to contextualize in vitro transport data of discovery compounds by benchmarking the in vitro transport data of reference drug dantrolene and taking into account inter-batch variation in BCRP protein expression. This approach correctly predicted impaired brain penetration for compounds, which are BCRP but not or weak P-gp substrates.
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